Literature DB >> 6121576

The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.

A K Azadkhan, S C Truelove, J K Aronson.   

Abstract

1 We have investigated the disposition and metabolism of sulphasalazine (SASP) in eight adults with and without inflammatory bowel disease. 2 SASP is poorly absorbed (less than 12%) and the half-time measured in the serum, 10.2 h, is probably the half-time of absorption and therefore an overestimate of the true half-time. The apparent volume of distribution is low (less than 9 l). Renal and biliary clearance rates are low (5.5 and 2.1 ml min-1 respectively) probably due to a high degree of protein binding. Of the absorbed SASP, two thirds is excreted in the urine and one third in the bile. 3 Most of the SASP reaches the colon and is there split by bacteria, forming sulphapyridine (SP) and 5-aminosalicylic acid (5-ASA). 4 SP is almost completely absorbed and, with its metabolites, is excreted in the urine (SP renal clearance rate 32.1 ml min-1). There is no enterohepatic recirculation. 5 Of the 5-ASA released in the colon at least 25% is absorbed and rapidly eliminated in the urine after acetylation. At least 50% is eliminated in the faeces. 6 There are no differences in disposition characteristics when comparing patients with and without inflammatory bowel disease but the metabolism of SASP is markedly reduced in patients taking antibiotics and after removal of the large bowel.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6121576      PMCID: PMC1402052          DOI: 10.1111/j.1365-2125.1982.tb01415.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Distribution and metabolism of salicyl-azo-sulfapyridine. I. A study with C-14-5-amino-salicylic acid.

Authors:  A HANNGREN; E HANSSON; N SVARTZ; S ULLBERG
Journal:  Acta Med Scand       Date:  1963-01

2.  Absorption, metabolism, and excretion of salicylazosulfapyridine in man.

Authors:  H Schröder; D E Campbell
Journal:  Clin Pharmacol Ther       Date:  1972 Jul-Aug       Impact factor: 6.875

3.  Distribution studies of salicylazosulfapyridine and its metabolites.

Authors:  M A Peppercorn; P Goldman
Journal:  Gastroenterology       Date:  1973-02       Impact factor: 22.682

4.  Is plasma level monitoring of sulfasalazine indicated in the treatment of Crohn's disease or ulcerative colitis?

Authors:  C Fischer; U Klotz
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

5.  Metabolism of salicylazosulfapyridine in healthy subjects and in patients with ulcerative colitis. Effects of colectomy and of phenobarbital.

Authors:  H Schröder; R M Lewkonia; D A Price Evans
Journal:  Clin Pharmacol Ther       Date:  1973 Sep-Oct       Impact factor: 6.875

6.  Determination of salicylazosulphapyridine in biological materials.

Authors:  M Sandberg; K A Hansson
Journal:  Acta Pharm Suec       Date:  1973-05

7.  Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine.

Authors:  K A Hansson; M Sandberg
Journal:  Acta Pharm Suec       Date:  1973-03

8.  Determination of free and acetylated 5-aminosalicylic acid in serum and urine after administration of salicylazosulphapyridine.

Authors:  K A Hansson
Journal:  Acta Pharm Suec       Date:  1973-05

9.  The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  Gut       Date:  1973-08       Impact factor: 23.059

  9 in total
  34 in total

1.  Sulfasalazine for brain cancer fits.

Authors:  Harald Sontheimer; Richard J Bridges
Journal:  Expert Opin Investig Drugs       Date:  2012-03-12       Impact factor: 6.206

2.  Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP.

Authors:  Hiroyuki Kusuhara; Hidetoshi Furuie; Akihiro Inano; Akihiro Sunagawa; Saiko Yamada; Chunyong Wu; Shinya Fukizawa; Nozomi Morimoto; Ichiro Ieiri; Mariko Morishita; Kiminobu Sumita; Hiroshi Mayahara; Takuya Fujita; Kazuya Maeda; Yuichi Sugiyama
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 3.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

4.  Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease.

Authors:  Rajkumar Malayandi; Phani Krishna Kondamudi; P K Ruby; Deepika Aggarwal
Journal:  Drug Deliv Transl Res       Date:  2014-04       Impact factor: 4.617

5.  Pharmacokinetics of sulfasalazine metabolites in rats following concomitant oral administration of riboflavin.

Authors:  V S Chungi; L W Dittert; L Shargel
Journal:  Pharm Res       Date:  1989-12       Impact factor: 4.200

6.  Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine.

Authors:  H Allgayer; J Eisenburg; G Paumgartner
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

8.  Modulation of human colonic arachidonic acid metabolism by sulfasalazine.

Authors:  C J Hawkey; N K Boughton-Smith; B J Whittle
Journal:  Dig Dis Sci       Date:  1985-12       Impact factor: 3.199

9.  The effect of age and acetylator phenotype on the pharmacokinetics of sulfasalazine in patients with rheumatoid arthritis.

Authors:  A J Taggart; B J McDermott; S D Roberts
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

10.  Stability of disodium azodisalicylate (olsalazine) and metabolites in urine and faeces stored at different temperatures.

Authors:  R A van Hogezand; A van Schaik; P A van Hees; J H van Tongeren
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Oct-Dec       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.